# US 2026/0295054 A1 · Glucagon-like peptide-1 receptor agonist variants and methods thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0295054 A1
- Document ID: US20260295054A1
- Status: Published application
- Kind: A1
- Application number: 19/479,324
- Filed: 2024-04-30
- Published: 2026-10-01
- Earliest claimed: 2023-05-01
- Applicants: Neuraly, Inc.
- Inventors: Yen Huei LIN; Jaehee SHIN; Subramanya KARANTH; Adam BELL; Viktor ROSCHKE
- Web page: https://patentgrep.com/patent/US20260295054A1

## CPC

- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- C07K 14/605: Glucagons
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Glucagon-like peptide-1 (GLP-1) receptor agonists and analogs thereof having one or more amino acids substituted to reduce immunogenicity and antigenicity are described. These GLP-1R agonists and analogs have comparable or better physicochemical properties and pharmacokinetics in a mammalian host relative to GLP-1 RAs currently available for treatment. Compositions and formulations of these agonist peptides are particularly suited for treating, alleviating, and/or preventing one or more metabolic diseases such as obesity, diabetes mellitus, and non-alcoholic fatty liver disease, as well as one or more neurodegenerative disease such as Alzheimer's disease (AD) and Parkinson's disease (PD).

## Claims

### Claim 1

A Glucagon-like peptide-1 receptor agonist (GLP-1 RA) peptide or analog thereof having activities towards a GLP-1 receptor, comprising the amino acid sequence of
(SEQ ID NO: 1)
HGX3GX5X6X7X8X9X10X11X12X13X14X15X16X17X18X19X20
X21X22X23X24WX26X27NGGPX32X33GX35PPPX39C,
wherein Xn is each independently selected from the amino acids for the specific positions:
X3 is E, D, K, or Q;
X5 is S or T;
X6 is F or Y;
X7 is S or T;
X8 is S, or A, D, E, G, K, N, Q, or T;
X9 is D, P, or E;
X10 is L, F, I, M, or V;
X11 is S, A, D, E, G, K, N, Q, or T;
X12 is K, E, Q, or R;
X13 is Q, E, K, or R;
X14 is M, R, L, or V;
X15 is E, D, K, or Q;
X16 is E, D, K, or Q;
X17 is E, D, K, or Q;
X18 is A, G, S, T, or V;
X19 is A, I, L, M, T, or V;
X20 is R, K, or Q;
X21 is L, F, I, M, or V;
X22 is F or Y;
X23 is I, G, L, F, M, or V;
X24 is E, D, K, or Q;
X26 is L, F, I, M, or V;
X27 is K, E, Q, or R;
X32 is S, A, D, E, G, K, N, Q, or T;
X33 is S, A, D, E, G, K, N, Q, or T;
X35 is A, G, S, T, or V; and
X39 is S, A, D, E, G, K, N, Q, or T.

### Claim 2 (depends on 1)

The GLP-1RA peptide or analog of claim 1, comprising the amino acid sequence of HGEGTFTSX9LSKQMEEEAX19RLFX23EWLKNGGPSSGX35PPPSC (SEQ ID NO: 2).

### Claim 3 (depends on 1)

The GLP-1RA peptide or analog of claim 1, wherein X19 is not a valine.

### Claim 4 (depends on 1)

The GLP-IRA peptide or analog of claim 1, wherein X19 is A or T.

### Claim 5 (depends on 1)

The GLP-1RA peptide or analog of claim 1, wherein X23 is G.

### Claim 6 (depends on 1)

The GLP-1RA peptide or analog of claim 1, wherein X9 is P and X23 is G.

### Claim 7 (depends on 1)

The GLP-1RA peptide or analog of claim 1, comprising the amino acid sequence of any one of SEQ ID NOs: 2-7.

### Claim 8 (depends on 1)

The GLP-1RA peptide or analog of claim 1, comprising the amino acid sequence of SEQ ID NO: 5.

### Claim 9 (depends on 1)

The GLP-1RA peptide or analog of claim 1, having a substantially lower immunogenicity in a mammalian host, preferably, human host, relative to immunogenicity of SEQ ID NO: 3.

### Claim 10 (depends on 1)

The GLP-1RA peptide or analog of claim 1, wherein the GLP-1RA peptide or analog is conjugated to one or more polyethylene glycol (PEG) moieties.

### Claim 11 (depends on 1)

The GLP-IRA peptide or analog of claim 1, wherein the peptide or analog is conjugated to one or more multiple-branched PEGs.

### Claim 12 (depends on 10)

The GLP-1RA peptide or analog of claim 10, wherein the multiple-branched PEG has a molecular weight of between 20 kDa and 250 kDa.

### Claim 13

The GLP-IRA peptide or analog of 12, wherein the multiple-branched polyethylene glycol is a 3-arm branched PEGs having a molecular weight of between 20 kDa and 250 kDa.

### Claim 14 (depends on 13)

The GLP-1RA peptide or analog of claim 13, wherein the 3-arm branched PEGs having one of the following structures:
wherein m, n, j, k each is an integer independently between about 100 and 5,000.

### Claim 15 (depends on 11)

The GLP-1RA peptide or analog of claim 11, wherein the multiple-branched polyethylene glycol is a 3-arm branched PEGs having a molecular weight of about 50 kDa.

### Claim 16 (depends on 11)

The GLP-1RA peptide or analog of claim 11, wherein the peptide or analog conjugated to one or more polyethylene glycol (PEG) moieties comprises any one of SEQ ID NOs: 7-13.

### Claim 17 (depends on 1)

The GLP-1RA peptide or analog of claim 1, wherein the GLP-1RA peptide or analog comprises the amino acid sequence of SEQ ID NO: 5, and conjugated via C-terminal cysteine residue a 3-arm branched PEGs having one of the following structures:
wherein m, n, j, k each is an integer independently between about 100 and 5,000, wherein the 3-arm branched PEG has a molecular weight of about 50 kDa.

### Claim 18 (depends on 1)

A pharmaceutical formulation comprising the GLP-1RA peptide or analog of claim 1.

### Claim 19 (depends on 18)

A method of treating one or more diseases selected from the group consisting of obesity, diabetes, and non-alcoholic fatty liver disease in a subject in need thereof, comprising administering to an effective amount of the pharmaceutical formulation of claim 18 to treat or alleviate one or more symptom of the one or more diseases.

### Claim 20 (depends on 19)

The method of claim 19, wherein the pharmaceutical formulation is administered in an amount effective to induce weight loss, reduce the body fat, reduce food intake, improve glucose homeostasis, or combinations thereof, in a normal or obese patient.

### Claim 21 (depends on 19, 20)

The method of claim 19 or 20, wherein the pharmaceutical formulation is administered via a route selected from the group consisting of enteral administration and parenteral administration.

### Claim 22 (depends on 21)

The method of claim 21, wherein the pharmaceutical formulation is administered via oral administration or subcutaneous administration.

### Claim 23 (depends on 21)

The method of claim 21, wherein the pharmaceutical formulation is administered in a form selected from the group consisting of pills, capsules, tablets, liquids, and suspensions.

### Claim 24 (depends on 19)

The method of claim 19, wherein the pharmaceutical formulation is administered at an interval of once a month, once every two weeks, once a week, or less frequent.

### Claim 25 (depends on 19)

The method of claim 19, wherein the pharmaceutical formulation is administered the subject once a month.

### Claim 26 (depends on 19)

The method of claim 19, wherein the pharmaceutical formulation is administered to the subject for a duration of between one and 10 year, inclusive.

### Claim 27 (depends on 19)

The method of claim 19, wherein the pharmaceutical formulation is administered to a human subject at a dose of between 0.001 mg/kg body weight of the subject and 10 mg/kg body weight of the subject, inclusive.

### Claim at position 28

28-29. (canceled)

### Claim 30 (depends on 19)

The method of claim 19, wherein the pharmaceutical formulation provides a therapeutically effective concentration of the GLP-IRA peptide or analog in the serum of the subject throughout the treatment once a steady state is established after administration.

### Claim 31 (depends on 30)

The method of claim 30, wherein the therapeutically effective concentration of the GLP-1RA peptide or analog in the serum of the subject during the treatment does not fall below pharmacologically active levels.

### Claim 32

(canceled)

### Claim 33 (depends on 19)

The method of claim 19, wherein the pharmaceutical formulation results in less incidence of nausea and vomiting and better gastrointestinal (GI) tolerance compared to albiglutide when both are administered once monthly.

### Claim 34 (depends on 19)

The method of claim 19, wherein the pharmaceutical formulation provides a minimal serum concentration of about 27 nanomolar throughout the treatment once a steady state is established after administration.
